NeoGenomics, Inc.

NEO ·Healthcare, Diagnostics & Research, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012
Revenue $240.3M $231.8M $5.0M $5.0M $5.0M $5.0M
Cost of Revenue $138.3M $133.7M
Gross Profit $102.0M $98.1M $43.8M $40.7M $31.7M $26.8M
Gross Margin 42.4% 42.3% 875.1% 814.3% 634.7% 536.7%
Operating Expenses
Research & Development $3.6M $4.6M $4.2M $2.7M $2.4M $2.3M
SG&A Expense $70.4M $63.9M $33.6M $23.8M $17.4M $15.8M
Operating Income $2.9M $2.2M $-5.6M $2.2M $3.2M $1.2M
Operating Margin 1.2% 0.9% -112.7% 44.4% 63.5% 24.2%
Interest Expense $5.5M $854.0K $985.0K $989.0K $1.1M
Pretax Income $-2.7M $-7.8M $-4.5M $1.3M $2.2M $65.0K
Income Tax Expense $-2.3M $-1.7M $-2.0M $157.0K $152.0K $0
Net Income $-396.0K $-6.1M $-2.5M $1.1M $2.0M $65.0K
Net Margin -0.2% -2.6% -50.7% 22.6% 40.7% 1.3%
EPS (Basic) $-0.14 $-0.40 $-0.04 $0.02 $0.04 $0.00
EPS (Diluted) $-0.14 $-0.40 $-0.04 $0.02 $0.04 $0.00
Shares Outstanding (Basic) 79.4M 77.5M 60.5M 53.5M 48.3M 45.0M
Shares Outstanding (Diluted) 79.4M 77.5M 60.5M 56.0M 52.8M 48.7M
Dividends Per Share
← Newer Page 2 of 2 Older →